Total | Group 1 | Group 3 | |||
Overall | No prior antibiotics | Prior antibiotics | |||
Organisms n | 154 | 8 | 146 | 37 | 109 |
“Potentially resistant” bacteria | 75 (48.8) | 0 | 75 (48.8) | 8 (21.6)# | 67 (61.5) |
P. aeruginosa | 48 (31.2) | 0 | 48 (31.2) | 6 (16.2) | 42 (38.5) |
Acinetobacter spp. | 9 (5.8) | 0 | 9 (5.8) | 0 | 9 (8.3) |
S. maltophilia | 8 (5.2) | 0 | 8 (5.2) | 1 (2.7) | 7 (6.4) |
MRSA | 10 (6.5) | 0 | 10 (6.5) | 1 (2.7) | 9 (8.3) |
“Truly resistant” bacteria | 36 (23.4) | 0 | 36 (23.4) | 3 (8.1)¶ | 33 (30.3) |
Ticarcillin resistant P. aeruginosa | 5 (3.2) | 0 | 5 (3.2) | 1 (2.7) | 4 (3.7) |
Acinetobacter spp. | 9 (5.8) | 0 | 9 (5.8) | 0 | 9 (8.3) |
S. maltophilia | 8 (5.2) | 0 | 8 (5.2) | 1 (2.7) | 7 (6.3) |
MRSA | 10 (6.5) | 0 | 10 (6.5) | 1 (2.7) | 9 (8.3) |
ESBL producing enterobacteriaceae | 4 (2.6) | 0 | 4 (2.6) | 0 | 4 (3.7) |
Data are presented as n (%)
P. aeruginosa: Pseudomonas aeruginosa
S. maltophilia: Stenotrophomonas maltophilia
MRSA: methicillin resistant Staphylococcus aureus
ESBL: extended-spectrum β‐lactamase
#: p<0.0001 versus patients with prior antibiotics
¶: p=0.003 versus patients with prior antibiotics